Eli Lilly and Company $LLY Shares Purchased by CreativeOne Wealth LLC

Key Points

• CreativeOne Wealth LLC has increased its position in Eli Lilly and Company (LLY) by 28.9%, now owning 12,755 shares valued at approximately $10.5 million.
• Eli Lilly's stock recently reported a 5.7% increase with a market cap of $695.58 billion, and the company's quarterly earnings beat expectations, reporting $6.31 earnings per share on $15.56 billion revenue.
• The company announced a quarterly dividend of $1.50 per share, reflecting a 0.8% yield and a payout ratio of 39.22%.

CreativeOne Wealth LLC increased its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 28.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,755 shares of the company's stock after purchasing an additional 2,856 shares during the period. CreativeOne Wealth LLC's holdings in Eli Lilly and Company were worth $10,535,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also bought and sold shares of the company. WestEnd Advisors LLC boosted its position in Eli Lilly and Company by 210.0% during the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after purchasing an additional 21 shares in the last quarter. Citizens National Bank Trust Department increased its stake in shares of Eli Lilly and Company by 180.0% during the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after purchasing an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. purchased a new stake in shares of Eli Lilly and Company during the first quarter worth about $40,000. Mascagni Wealth Management Inc. acquired a new position in Eli Lilly and Company during the fourth quarter worth about $43,000. Finally, O Brien Wealth Partners LLC boosted its position in Eli Lilly and Company by 25.5% during the first quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock worth $49,000 after acquiring an additional 12 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, Director Gabrielle Sulzberger bought 117 shares of the business's stock in a transaction on Tuesday, August 12th. The stock was bought at an average price of $641.18 per share, for a total transaction of $75,018.06. Following the completion of the transaction, the director owned 2,703 shares in the company, valued at approximately $1,733,109.54. The trade was a 4.52% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director J Erik Fyrwald bought 1,565 shares of the business's stock in a transaction on Tuesday, August 12th. The shares were acquired at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the transaction, the director owned 74,578 shares of the company's stock, valued at $47,903,686.74. The trade was a 2.14% increase in their position. The disclosure for this purchase can be found here. Insiders have acquired a total of 4,514 shares of company stock valued at $2,894,841 in the last quarter. 0.13% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

LLY has been the topic of several recent analyst reports. Leerink Partnrs lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Thursday, August 7th. Wall Street Zen upgraded shares of Eli Lilly and Company from a "buy" rating to a "strong-buy" rating in a report on Friday, August 22nd. HSBC upgraded shares of Eli Lilly and Company from a "reduce" rating to a "hold" rating and boosted their target price for the stock from $675.00 to $700.00 in a research note on Wednesday. Morgan Stanley reaffirmed an "overweight" rating and set a $1,135.00 price objective (up from $1,133.00) on shares of Eli Lilly and Company in a research report on Thursday, July 10th. Finally, Deutsche Bank Aktiengesellschaft decreased their target price on Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating for the company in a research note on Monday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, Eli Lilly and Company has an average rating of "Moderate Buy" and an average price target of $950.17.

Eli Lilly and Company Price Performance

LLY stock traded up $0.45 during trading on Friday, reaching $732.41. 2,548,350 shares of the company were exchanged, compared to its average volume of 4,168,969. The company has a market cap of $693.20 billion, a P/E ratio of 47.87, a PEG ratio of 1.02 and a beta of 0.44. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $969.65. The stock's 50 day moving average price is $749.30 and its 200 day moving average price is $787.01. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm's quarterly revenue was up 37.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be given a dividend of $1.50 per share. The ex-dividend date is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a yield of 0.8%. Eli Lilly and Company's payout ratio is presently 39.22%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.